1. Antibacterials Market to 2017 - Innovative Anti-Infectives that
Target MDR Gram-Negative Pathogens Offer Significant
Revenue Potential
Report Details:
Published:May 2012
No. of Pages: 145
Price: Single User License – US$3500
Corporate User License – US$10500
Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative
Pathogens Offer Significant Revenue Potential
Summary
GBI Research, the leading business intelligence provider, has released its latest report,
“Antibacterials Market to 2017 - Innovative Anti-Infectives that Target MDR Gram-Negative
Pathogens Offer Significant Revenue Potential”, which provides key data, information and analysis
for the global antibacterials market (covering tuberculosis, pneumonia, urinary tract infections,
atypical bronchitis, tonsillitis, sinusitis and otitis media in the US, the top five countries in Europe
and Japan).
This report offers a comprehensive insight into antibacterial market based on the seven indications
covered. It provides a disease overview for each indication, market forecasting, drivers and
barriers, key marketed products, pipeline information and deals information for each disease in the
top seven markets, as well as profiles for the main companies operating in the market.
The report is based on proprietary databases, primary and secondary research and in-house
analysis by GBI Research’s team of industry experts to provide a comprehensive view of the
antibacterials market.
The market is large and established, but still seeing good growth despite this due to the increasing
problem of nosocomial infection and the increasing incidence of some bacterial diseases in the
developed world. Despite several patent expiries, including of Levaquin, one of the highest selling
antibacterials, growth will continue over the forecast period. Antibacterial stewardship programs for
general practitioners and hospitals, aimed at countering the development of resistance in bacteria,
2. will not significantly slow revenues in the forecast period. While the development of new
antibacterials is not currently a hugely dynamic area, targeting multi-drug resistant TB and other
indications will require innovative solutions in the future.
The antibacterials market is expected to reach $12.7 billion in 2017, growing from $11.3 billion in
2010 at a CAGR of 1.7%. The market is well served currently and patent expiries are slowing the
overall growth. However, despite this saturation, hospital-acquired infections are providing an
impetus to development.
Scope
- Overview of the global market for antibacterials.
- Breakdown of the market by region.
- Market analysis for each indication – including disease overviews, market forecasting, annual
cost of therapy, treatment usage patterns, key marketed products and drivers and barriers.
- Comprehensive pipeline analysis by indications across all phases of development.
- Company profiles including SWOT analysis for major companies operating in the market.
- Key deals in the antibacterials space.
Reasons to buy
- Make more informed business decisions from the insightful and in-depth analysis of the
antibacterials market.
- Identify the opportunities and challenges that exist within the antibacterials market.
- Build effective strategies to launch pipeline products.
- Identify the opportunities for collaboration with the participants in the antibacterials market.
Get your copy of this report @
http://www.reportsnreports.com/reports/144408-antibacterials-market-to-2017-innovative-anti-infectives-that-
target-mdr-gram-negative-pathogens-offer-significant-revenue-potential.html
Major points covered in Table of Contents of this report include
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 10
1.2 List of Figures 12
2 Antibacterials - Introduction 14
3 Antibacterials - Overview 15
3.1 Bacterial Classification 15
3.1.1 Antimicrobial Spectrum 15
3.1.2 Bacterial Resistance 16
3.2 Antibacterial Classification 16
3.2.1 Cephalosporin Antibacterials 16
3. 3.2.2 Penicillin Antibacterials 19
3.2.3 Quinolone Antibacterials 20
3.2.4 Macrolide Antibacterials 21
3.3 Global Revenues for Antibacterials 21
3.3.1 Global Revenue and Forecast 21
3.3.2 Revenue Share by Indication 23
3.4 The US 24
3.4.1 Total Revenues 24
3.5 Europe (The UK, France, Germany, Spain, Italy) 25
3.5.1 Total Revenues 25
3.6 Japan 27
3.6.1 Total Revenues 27
3.7 Drivers and Barriers for the Antibacterials Market 28
3.7.1 Drivers for the Antibacterials Market 28
3.7.2 Barriers for the Antibacterials Market 28
3.8 Opportunities 31
3.8.1 Alliances with Academic and Research Institutions are the Way Forward for Big Pharma 31
4 Tuberculosis 32
4.1 Overview 32
4.1.1 Microbiology 33
4.1.2 Diagnosis 33
4.1.3 Treatment 33
4.1.4 Prevention 34
4.2 Tuberculosis Therapeutics Market Size 35
4.2.1 Total Revenue 35
4.2.2 Average Annual Cost of Treatment (ACT) 38
4.2.3 Treatment Usage Patterns 39
4.3 Drivers and Barriers for the Tuberculosis Therapeutics Market 42
4.3.1 Drivers for the Tuberculosis Therapeutics Market 42
4.3.2 Barriers to the Tuberculosis Therapeutics Market 43
4.4 Product Profile of the Major Marketed Products in the Tuberculosis Market 43
4.4.1 Isoniazid (Isonicotinylhydrazine, INH) 43
4.4.2 Rifampin (RIF) 44
4.4.3 Pyrazinamide (PZA) 44
4.4.4 Ethambutol (EMB) 45
5 Pneumonia 46
5.1 Overview 46
5.1.1 Microbiology 46
5.1.2 Diagnosis 46
5.1.3 Treatment 47
5.1.4 Prevention 48
4. 5.2 Pneumonia Therapeutics Market Size 49
5.2.1 Total Revenue 49
5.2.2 Annual Cost of Treatment (ACT) 52
5.2.3 Treatment Usage Patterns 53
5.3 Drivers and Barriers to the Pneumonia Therapeutics Market 55
5.3.1 Drivers for the Pneumonia Therapeutics Market 55
5.3.2 Barriers to the Pneumonia Antibacterials Market 55
5.4 Product Profile of the Major Marketed Products in the Pneumonia Antibacterials Market 57
5.4.1 Zyvox (linezolid) 57
5.4.2 Zosyn (piperacillin and tazobactum) 58
5.4.3 Levaquin (levofloxacin) 58
5.4.4 Avelox (moxifloxacin) 59
5.4.5 Omnicef (cefnidir) 59
5.4.6 Tygacil (tigecycline) 60
5.4.7 Doribax (doripenem) 61
6 Urinary Tract Infections 62
6.1 Overview 62
6.1.1 Cystitis 62
6.1.2 Urethritis 62
6.1.3 Pyelonephritis 62
6.1.4 Microbiology 62
6.1.5 Diagnosis 62
6.1.6 Urinalysis 62
6.1.7 Urine Culture 62
6.1.8 Treatment 63
6.1.9 Prevention 64
6.2 Urinary Tract Infection Therapeutics Market Size 64
6.2.1 Total Revenue 64
6.2.2 Annual Cost of Treatment (ACT) 67
6.2.3 Treatment Usage Patterns 68
6.3 Drivers and Barriers for the Urinary Tract Infection Therapeutics Market 70
6.3.1 Drivers for the UTI Therapeutics Market 70
6.3.2 Barriers for the UTI Therapeutics Market 70
6.4 Product Profile of the Major Marketed Products in the Urinary Tract Infection Market 71
6.4.1 Doribax (doripenem) 71
6.4.2 Ciprofloxacin 72
6.4.3 Levaquin (levafloxacin) 73
6.4.4 Monurol (fosfomycin tromethamine) 74
6.4.5 Macrobid (nitrofurantoin) 74
7 Atypical Bronchitis 76
7.1 Overview 76
5. 7.1.1 Microbiology 76
7.1.2 Diagnosis 76
7.1.3 Treatment 76
7.1.4 Prevention 76
7.2 Atypical Bronchitis Therapeutics Market Size 77
7.2.1 Total Revenue 77
7.2.2 Annual Cost of Treatment (ACT) 79
7.2.3 Treatment Usage Patterns 80
7.3 Drivers and Barriers for the Atypical Bronchitis Therapeutics Market 82
7.3.1 Drivers for the Atypical Bronchitis Therapeutics Market 82
7.3.2 Barriers for the Atypical Bronchitis Therapeutics Market 82
7.4 Marketed Products 83
8 Tonsillitis 84
8.1 Overview 84
8.1.1 Microbiology 84
8.1.2 Diagnosis 84
8.1.3 Treatment 84
8.1.4 Prevention 85
8.2 Tonsillitis Therapeutics Market Size 85
8.2.1 Total Revenue 85
8.2.2 Annual Cost of Treatment (ACT) 87
8.2.3 Treatment Usage Patterns 88
8.3 Drivers and Barriers for the Tonsillitis Therapeutics Market 90
8.3.1 Drivers for the Tonsillitis Therapeutics Market 90
8.3.2 Barriers for the Tonsillitis Therapeutics Market 90
8.4 Marketed Products 91
8.4.1 Spectracef 91
9 Sinusitis 92
9.1 Overview 92
9.1.1 Frontal Sinusitis (located behind the forehead) 92
9.1.2 Ethmoid Sinusitis (behind the bridge of the nose) 92
9.1.3 Sphenoid Sinusitis (behind the eyes) 92
9.1.4 Maxillary Sinusitis (behind the cheeks) 92
9.1.5 Acute Sinusitis 92
9.1.6 Chronic Sinusitis 92
9.1.7 Microbiology 93
9.1.8 Diagnosis 93
9.1.9 Treatment 93
9.1.10 Prevention 93
9.2 Sinusitis Therapeutics Market Size 94
9.2.1 Total Revenue 94
6. 9.2.2 Annual Cost of Therapy 96
9.2.3 Therapeutic Patterns 97
9.3 Drivers and Barriers for the Sinusitis Therapeutics Market 98
9.3.1 Drivers for the Sinusitis Therapeutics Market 98
9.3.2 Barriers for the Sinusitis Therapeutics Market 99
9.4 Marketed Products 99
9.4.1 Augmentin 99
9.4.2 Levaquin 100
9.4.3 Doryx 101
10 Otitis Media 102
10.1 Overview 102
10.1.1 Acute 102
10.1.2 Serous 102
10.1.3 Chronic Suppurative 102
10.2 Otitis Media Therapeutics Market Size 103
10.2.1 Total Revenue 103
10.2.2 Annual Cost of Therapy 105
10.2.3 Therapeutic Patterns 106
10.3 Drivers and Barriers for the Otitis Media Therapeutics Market 107
10.3.1 Drivers for the Otitis Media Therapeutics Market 107
10.3.2 Barriers for the Otitis Media Therapeutics Market 107
10.4 Marketed Products 108
10.4.1 Amoxicillin 108
11 Antibacterials - Pipeline Analysis 109
11.1 Introduction 109
11.2 Global Tuberculosis Market: Pipeline Analysis 110
11.2.1 Overview 110
11.2.2 Research and Development Pipeline - Phase III 110
11.2.3 Research and Development Pipeline - Phase II 111
11.2.4 Research and Development Pipeline - Phase I 112
11.2.5 Research and Development Pipeline - Preclinical 112
11.3 Global Pneumonia Therapeutics Market: Pipeline Assessment 113
11.3.1 Overview 113
11.3.2 NDA Filed 113
11.3.3 Phase III 113
11.3.4 Phase II 114
11.3.5 Phase I 115
11.3.6 Preclinical 115
11.4 Global Urinary Tract Infection Therapeutics Market: Pipeline Assessment 116
11.4.1 Overview 116
11.4.2 Phase III 116
7. 11.4.3 Phase II 117
11.4.4 Phase I 117
11.4.5 Discovery 117
11.5 Global Atypical Bronchitis Therapeutics Market: Pipeline Assessment 118
11.5.1 Phase I 118
11.6 Global Tonsillitis Therapeutics Market: Pipeline Assessment 118
11.6.1 Overview 118
11.7 Global Sinusitis Therapeutics Market: Pipeline Assessment 118
11.7.1 Phase I 118
11.8 Global Otitis Media Therapeutics Market: Pipeline Assessment 119
11.8.1 Overview 119
11.8.2 Phase II 119
11.8.3 Preclinical 119
12 Antibacterials: Competitive Landscape 120
12.1 Major Players 120
12.2 Major Company Profiles 120
12.2.1 Pfizer 120
12.2.2 Sanofi 121
12.2.3 Bayer 122
12.2.4 GlaxoSmithKline 123
12.2.5 AstraZeneca 124
12.2.6 Cubist 125
12.2.7 Daiichi Sankyo 126
12.2.8 Tetraphase 127
12.2.9 Johnson and Johnson 128
13 Antibacterials - Strategic Consolidations 129
13.1 Overview - Antibacterials Market 129
13.1.1 Deals by Indication 129
13.1.2 Deals by Year 130
13.2 Tuberculosis 130
13.2.1 Mergers and Acquisitions 130
13.2.2 Licensing and Co-Developments 130
13.3 Pneumonia 133
13.3.1 Furiex Pharmaceuticals Enters into Licensing Agreement with Janssen Pharmaceutica for
JNJ-Q2 (April 19, 2011) 133
13.3.2 TaiGen Biotechnology Amends its Licensing Agreement with Warner Chilcott for
Nemonoxacin (October 14, 2010) 133
13.3.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29,
2010) 134
13.3.4 Paratek Pharmaceuticals Enters into Licensing Agreement with Novartis (October 8, 2009)
134
8. 13.3.5 AstraZeneca Enters into Co-Development Agreement with Forest Laboratories (August 12,
2009) 134
13.3.6 Protea Vaccine Enters into Co-Development Agreement with GlaxoSmithKline Biologicals
(June 16, 2009) 134
13.3.7 Sanofi-aventis Enters into Licensing and Collaboration Agreement with Novozymes
(December 22, 2008) 135
13.3.8 Laboratorios Farmaceuticos ROVI Enters into Co-Development Agreement with Sanofi
Pasteur (May 5, 2008) 135
13.3.9 Aridis Pharmaceuticals Enters into Licensing Agreement with University of Iowa Research
(February 19, 2008) 135
13.3.10 Nektar Therapeutics Enters into Co-Development Agreement with Bayer HealthCare
(August 6, 2007) 135
13.3.11 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for
FACTIVE (January 4, 2007) 136
13.4 UTI 136
13.4.1 Teva Pharmaceutical Acquires CoGenesys from New Enterprise, Orbimed and Red Abbey
(February 21, 2008) 136
13.4.2 NanoBio Enters into Licensing Agreement with University of Michigan (April 20, 2011) 136
13.4.3 Anacor Pharmaceuticals Enters into Licensing Agreement with GlaxoSmithKline (June 29,
2010) 136
13.4.4 Depomed Amends Licensing Agreement with Madaus (April 30, 2009) 137
13.5 Atypical Bronchitis 137
13.5.1 Teva Pharmaceutical Industries Completes Acquisition of Ratiopharm (August 10, 2010)
137
13.6 Tonsillitis 137
13.6.1 Meiji Seika Enters into Licensing Agreement with Cornerstone Biopharma (November 9,
2006) 137
13.7 Sinusitis 138
13.7.1 Oscient Pharmaceuticals Enters into License Agreement with Menarini Group for FACTIVE
(January 4, 2007) 138
13.8 Otitis Media 138
13.8.1 MerLion Pharmaceuticals Enters into Licensing Agreement with Alcon Pharmaceuticals for
Finafloxacin (January 11, 2011) 138
13.8.2 OctoPlus Enters into Licensing Agreement with Green Cross (November 22, 2006) 138
14 Antibacterials - Appendix 139
14.1 Market Definition 139
14.2 Abbreviations 139
14.3 Sources 141
14.4 Research Methodology 141
14.4.1 Coverage 142
14.4.2 Secondary Research 142
